JP2023551355A5 - - Google Patents

Info

Publication number
JP2023551355A5
JP2023551355A5 JP2023520181A JP2023520181A JP2023551355A5 JP 2023551355 A5 JP2023551355 A5 JP 2023551355A5 JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023551355 A5 JP2023551355 A5 JP 2023551355A5
Authority
JP
Japan
Prior art keywords
here
group
ring
independently
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/121721 external-priority patent/WO2022068878A1/zh
Publication of JP2023551355A publication Critical patent/JP2023551355A/ja
Publication of JP2023551355A5 publication Critical patent/JP2023551355A5/ja
Pending legal-status Critical Current

Links

JP2023520181A 2020-09-30 2021-09-29 抗腫瘍化合物並びにその調製方法及び使用 Pending JP2023551355A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011061580 2020-09-30
CN202011061580.7 2020-09-30
PCT/CN2021/121721 WO2022068878A1 (zh) 2020-09-30 2021-09-29 一种抗肿瘤化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
JP2023551355A JP2023551355A (ja) 2023-12-08
JP2023551355A5 true JP2023551355A5 (cg-RX-API-DMAC7.html) 2024-10-08

Family

ID=80951198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520181A Pending JP2023551355A (ja) 2020-09-30 2021-09-29 抗腫瘍化合物並びにその調製方法及び使用

Country Status (21)

Country Link
US (7) US11685742B2 (cg-RX-API-DMAC7.html)
EP (2) EP4516357B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551355A (cg-RX-API-DMAC7.html)
KR (1) KR20230079085A (cg-RX-API-DMAC7.html)
CN (8) CN122005840A (cg-RX-API-DMAC7.html)
AU (1) AU2021354823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195515A1 (cg-RX-API-DMAC7.html)
DK (1) DK4516357T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067785T3 (cg-RX-API-DMAC7.html)
FI (1) FI4516357T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260401T1 (cg-RX-API-DMAC7.html)
IL (1) IL301793A (cg-RX-API-DMAC7.html)
LT (1) LT4516357T (cg-RX-API-DMAC7.html)
MX (1) MX2023003778A (cg-RX-API-DMAC7.html)
PL (1) PL4516357T3 (cg-RX-API-DMAC7.html)
PT (1) PT4516357T (cg-RX-API-DMAC7.html)
RS (1) RS68033B1 (cg-RX-API-DMAC7.html)
SI (1) SI4516357T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600197T1 (cg-RX-API-DMAC7.html)
TW (1) TW202214230A (cg-RX-API-DMAC7.html)
WO (1) WO2022068878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4516357T3 (da) * 2020-09-30 2026-04-27 Duality Biologics Suzhou Co Ltd Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
AU2022269073A1 (en) 2021-05-07 2023-11-23 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof
CN115557962A (zh) * 2021-07-02 2023-01-03 石药集团巨石生物制药有限公司 新型喜树碱类化合物及其制备方法和应用
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
CN115850291B (zh) * 2021-09-24 2024-11-15 石药集团巨石生物制药有限公司 喜树碱衍生物及其用途
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN118829450A (zh) * 2022-01-18 2024-10-22 甘李药业股份有限公司 一种依喜替康衍生物-抗体偶联物及其医药用途
EP4470570A1 (en) * 2022-01-28 2024-12-04 Duality Biologics (Suzhou) Co., Ltd. Her3 antibody-drug conjugate and use thereof
JP2025509286A (ja) * 2022-03-10 2025-04-11 ビバソル, インコーポレイテッド 抗体-薬物コンジュゲートおよびその使用
US20250195681A1 (en) * 2022-03-18 2025-06-19 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
TW202344252A (zh) * 2022-05-09 2023-11-16 大陸商同宜醫藥(蘇州)有限公司 一種喜樹鹼衍生物,基於其的抗體-藥物偶聯物和藥物組成物,及其應用
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
AU2023282410A1 (en) * 2022-06-07 2024-12-05 Duality Biologics (Suzhou) Co., Ltd. Anti-b7h3 antibody-drug conjugate and use thereof
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
CN117024438B (zh) * 2022-07-29 2026-05-05 杭州爱科瑞思生物医药有限公司 依沙替康衍生物及其应用
CN120225528A (zh) 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
AU2023349279A1 (en) * 2022-09-30 2025-05-15 Beone Medicines I Gmbh Ligand-drug conjugate of exatecan analogue, and medical use thereof
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
CN119855820A (zh) * 2022-12-16 2025-04-18 上海齐鲁制药研究中心有限公司 喜树碱类化合物及其制备方法和用途
KR20250128359A (ko) * 2022-12-27 2025-08-27 듀얼리티 바이올로직스 (상하이) 컴퍼니 리미티드 항 b7h3 및 pd-l1의 이중특이성 항체-약물 접합체 및 이의 제조 방법과 용도
NZ821249A (en) * 2022-12-28 2026-03-27 Adcendo Aps Antibody-drug conjugates targeting uparap comprising exatecan derivatives
CN116712561A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 含n-亚甲基酰胺连接子的抗体-药物偶联物
CN122080121A (zh) 2023-03-22 2026-05-26 映恩生物科技(上海)有限公司 连接子及其在配体药物偶联物中的应用
CN121038817A (zh) 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
CN120958033B (zh) * 2023-08-04 2026-03-31 映恩生物制药(苏州)有限公司 抗体药物偶联物的识别抗体及其应用
WO2025166725A1 (en) 2024-02-08 2025-08-14 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025056748A1 (en) 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025054996A1 (en) 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
TW202540115A (zh) 2023-11-16 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 一種氘代喜樹鹼化合物及其製備和應用
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
CN122374343A (zh) 2023-11-30 2026-07-10 江苏康宁杰瑞生物制药有限公司 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
WO2025162049A1 (zh) * 2024-02-02 2025-08-07 长春金赛药业有限责任公司 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用
TW202612739A (zh) 2024-05-16 2026-04-01 日商第一三共股份有限公司 抗b7-h3抗體-藥物結合物與雄性素受體傳訊抑制劑之組合
WO2025247255A1 (zh) * 2024-05-28 2025-12-04 映恩生物科技(上海)有限公司 一种抗dll3抗体、抗体药物偶联物及其应用
TW202613129A (zh) * 2024-05-31 2026-04-01 大陸商杭州中美華東製藥有限公司 一種喜樹鹼類化合物及其應用
CN122497675A (zh) * 2024-06-05 2026-07-31 荣昌生物制药(烟台)股份有限公司 一种喜树碱类化合物及其用途
EP4766727A1 (en) 2024-06-14 2026-07-01 Biontech SE Polytherapy for the treatment of cancer
WO2025256761A1 (en) 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
WO1999061061A1 (fr) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) * 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
SG11201603960XA (en) * 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US11185594B2 (en) * 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
WO2018066626A1 (ja) * 2016-10-07 2018-04-12 第一三共株式会社 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
CN109106951A (zh) 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
CN110016026B (zh) * 2018-01-08 2022-11-25 上海凌济生物科技有限公司 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途
UA130338C2 (uk) * 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) * 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
MX2022000449A (es) * 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
US12605459B2 (en) * 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
DK4516357T3 (da) * 2020-09-30 2026-04-27 Duality Biologics Suzhou Co Ltd Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
WO2022078279A1 (zh) 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
EP4227310A4 (en) 2020-10-12 2024-11-06 Sichuan Baili Pharmaceutical Co. Ltd. CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
CN114569739A (zh) 2020-12-01 2022-06-03 正大天晴药业集团股份有限公司 抗体药物偶联物
AU2022216696A1 (en) 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN113816969B (zh) 2021-04-30 2024-01-16 联宁(苏州)生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
AU2022269073A1 (en) 2021-05-07 2023-11-23 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof

Similar Documents

Publication Publication Date Title
JP7551056B2 (ja) プログラマブルなポリマー薬物
Drewry et al. Solid-phase synthesis of trisubstituted guanidines
WO2019071153A1 (en) PROGRAMMABLE DENDRITIC MEDICINES
JP2024050717A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
JP2021503450A (ja) プログラム可能なポリマー薬
KR20200108866A (ko) 생물학적 활성 화합물을 포함하는 강성 공간 군을 갖는 중합체
AU2013231819B2 (en) Aminoacid lipids
WO2019140128A1 (en) Phosphoalkyl polymers comprising biologically active compounds
JP7304128B2 (ja) 白金耐性の克服における使用のためのテキサフィリン-白金(iv)コンジュゲート及び組成物
AU2022252848B2 (en) Macrocyclic ligands with pendant chelating moieties and complexes thereof
US8962838B2 (en) Platinum complexes and their use
JP2024537069A (ja) ポリマーデュアル薬物の自動合成
JP2008517949A5 (cg-RX-API-DMAC7.html)
NL2020121B1 (en) Platinum-based functional moieties for preparing cell targeting conjugates
AU2018317611B2 (en) Non-natural amatoxin-type antibody conjugate
US20040142851A1 (en) Hydrazinopeptoids and their uses for treating cancers
CA2891593A1 (en) Di-macrocycles
CN105440059B (zh) 氨基酸与邻菲啰啉或其衍生物的铜配合物及其制备方法和应用
AU2012350146A1 (en) Functionalisation of cage amine ligands for metallo-radiopharmaceuticals
NL2020120B1 (en) Methods for preparing cell targeting conjugates and conjugates obtainable by said methods
CN104672213A (zh) 一种具有抗肿瘤活性的酰胺类化合物及其应用
US12304920B2 (en) Platinum complex, its preparation and therapeutic use
KR101426872B1 (ko) 금속 동위원소 표지를 위한 헤테로사이클릭 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법
TW202535475A (zh) 包含喜樹鹼衍生物之抗c-Met抗體-藥物綴合物
KR20250168470A (ko) 캄프토테신 유도체의 항체-약물 접합체 및 이의 용도